In light of the 2024 Shkreli Awards, how do you address patient concerns regarding the 240mg versus 960mg dose of sotorasib?  

There are some data indicating the 240mg daily dose may offer similar (though not statistically equivalent) oncologic outcomes with reduced symptoms and reduced financial toxicity, compared to the standard 960mg dose [PMID: 39029295]. This finding has recently been more publicized with the 2024 "Shkreli Awards" in which Amgen's decision to pursue approval for the 960mg dose is portrayed as profit-motivated. How do you discuss this data and developments with patients who express concerns they are potentially being over-dosed?